Type 1 treatments that once seemed far-fetched have taken major steps forward. We’ve seen continued commercialization of pump technology based on artificial pancreas algorithms, good news on the future of stem cell treatments and beta cell transplants, expansion in treatment options, and real competition among insulin manufacturers.